Cargando…

Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study

RATIONALE & OBJECTIVE: The risks of major bleeding, thrombosis, and cardiovascular events are elevated in patients receiving maintenance hemodialysis (HD). Our objective was to compare the risk of these outcomes in HD according to the permanent vascular access type. STUDY DESIGN: Observational c...

Descripción completa

Detalles Bibliográficos
Autores principales: Roetker, Nicholas S., Guo, Haifeng, Ramey, Dena Rosen, McMullan, Ciaran J., Atkins, G. Brandon, Wetmore, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189779/
https://www.ncbi.nlm.nih.gov/pubmed/35706716
http://dx.doi.org/10.1016/j.xkme.2022.100456
_version_ 1784725662222778368
author Roetker, Nicholas S.
Guo, Haifeng
Ramey, Dena Rosen
McMullan, Ciaran J.
Atkins, G. Brandon
Wetmore, James B.
author_facet Roetker, Nicholas S.
Guo, Haifeng
Ramey, Dena Rosen
McMullan, Ciaran J.
Atkins, G. Brandon
Wetmore, James B.
author_sort Roetker, Nicholas S.
collection PubMed
description RATIONALE & OBJECTIVE: The risks of major bleeding, thrombosis, and cardiovascular events are elevated in patients receiving maintenance hemodialysis (HD). Our objective was to compare the risk of these outcomes in HD according to the permanent vascular access type. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: Using data from the United States Renal Data System (2010-2015), we included patients with kidney failure who were greater than 18 years, had Medicare as the primary payer, were not using an oral anticoagulant, and were newly using an arteriovenous (AV) access for HD. EXPOSURE: AV graft (AVG) or AV fistula (AVF). OUTCOMES: Major bleeding, venous thromboembolism, ischemic stroke, myocardial infarction, cardiovascular death, and critical limb ischemia. ANALYTICAL APPROACH: Comparing 17,763 AVG and 60,329 AVF users, we estimated the 3-year incidence rates and incidence rate ratios (IRRs) of each outcome using Poisson regression. IRRs were adjusted for sociodemographic and clinical covariates. RESULTS: The use of an AVG, compared with that of an AVF, was associated with an increased risk of venous thromboembolism (10.8 vs 5.3 events per 100 person-years; adjusted IRR, 1.74; 95% CI, 1.63-1.85) but not with the risk of major bleeding (IRR, 1.04; 95% CI, 0.93-1.17). The use of an AVG was also potentially associated with a slightly increased risk of cardiovascular death (IRR, 1.09; 95% CI, 1.01-1.16). LIMITATIONS: This analysis focused on patients with a functioning AV access; adverse events that may occur during access maturation should also be considered when selecting a vascular access. CONCLUSIONS: The use of an AVG, relative to an AVF, in HD is associated with an increased risk of venous thromboembolism. Given recent guidelines emphasizing selection of the “right access” for the “right patient,” the results of this study should potentially be considered as one additional factor when selecting the optimal access for HD.
format Online
Article
Text
id pubmed-9189779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91897792022-06-14 Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study Roetker, Nicholas S. Guo, Haifeng Ramey, Dena Rosen McMullan, Ciaran J. Atkins, G. Brandon Wetmore, James B. Kidney Med Original Research RATIONALE & OBJECTIVE: The risks of major bleeding, thrombosis, and cardiovascular events are elevated in patients receiving maintenance hemodialysis (HD). Our objective was to compare the risk of these outcomes in HD according to the permanent vascular access type. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: Using data from the United States Renal Data System (2010-2015), we included patients with kidney failure who were greater than 18 years, had Medicare as the primary payer, were not using an oral anticoagulant, and were newly using an arteriovenous (AV) access for HD. EXPOSURE: AV graft (AVG) or AV fistula (AVF). OUTCOMES: Major bleeding, venous thromboembolism, ischemic stroke, myocardial infarction, cardiovascular death, and critical limb ischemia. ANALYTICAL APPROACH: Comparing 17,763 AVG and 60,329 AVF users, we estimated the 3-year incidence rates and incidence rate ratios (IRRs) of each outcome using Poisson regression. IRRs were adjusted for sociodemographic and clinical covariates. RESULTS: The use of an AVG, compared with that of an AVF, was associated with an increased risk of venous thromboembolism (10.8 vs 5.3 events per 100 person-years; adjusted IRR, 1.74; 95% CI, 1.63-1.85) but not with the risk of major bleeding (IRR, 1.04; 95% CI, 0.93-1.17). The use of an AVG was also potentially associated with a slightly increased risk of cardiovascular death (IRR, 1.09; 95% CI, 1.01-1.16). LIMITATIONS: This analysis focused on patients with a functioning AV access; adverse events that may occur during access maturation should also be considered when selecting a vascular access. CONCLUSIONS: The use of an AVG, relative to an AVF, in HD is associated with an increased risk of venous thromboembolism. Given recent guidelines emphasizing selection of the “right access” for the “right patient,” the results of this study should potentially be considered as one additional factor when selecting the optimal access for HD. Elsevier 2022-03-24 /pmc/articles/PMC9189779/ /pubmed/35706716 http://dx.doi.org/10.1016/j.xkme.2022.100456 Text en © 2022 Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc., Kenilworth, NJ, USA and The Author(s). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Roetker, Nicholas S.
Guo, Haifeng
Ramey, Dena Rosen
McMullan, Ciaran J.
Atkins, G. Brandon
Wetmore, James B.
Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study
title Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study
title_full Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study
title_fullStr Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study
title_full_unstemmed Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study
title_short Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study
title_sort hemodialysis vascular access and risk of major bleeding, thrombosis, and cardiovascular events: a cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189779/
https://www.ncbi.nlm.nih.gov/pubmed/35706716
http://dx.doi.org/10.1016/j.xkme.2022.100456
work_keys_str_mv AT roetkernicholass hemodialysisvascularaccessandriskofmajorbleedingthrombosisandcardiovasculareventsacohortstudy
AT guohaifeng hemodialysisvascularaccessandriskofmajorbleedingthrombosisandcardiovasculareventsacohortstudy
AT rameydenarosen hemodialysisvascularaccessandriskofmajorbleedingthrombosisandcardiovasculareventsacohortstudy
AT mcmullanciaranj hemodialysisvascularaccessandriskofmajorbleedingthrombosisandcardiovasculareventsacohortstudy
AT atkinsgbrandon hemodialysisvascularaccessandriskofmajorbleedingthrombosisandcardiovasculareventsacohortstudy
AT wetmorejamesb hemodialysisvascularaccessandriskofmajorbleedingthrombosisandcardiovasculareventsacohortstudy